- Fast Delivery
- 3rd Party Tested
- USA Manufactured
EU and UK, Allow 3-5 Working Days For Delivery
CJC 1295 is often discussed in relation to growth hormone and IGF I signalling. Anyone beginning to research the compound will soon encounter two names, CJC 1295 with DAC and CJC 1295 without DAC.
The simplest difference is duration.
DAC allows the peptide to remain in circulation for much longer, while the form without DAC does not contain the same albumin binding feature.
This difference helps explain the confusion behind the two.
It affects how the molecule behaves over time, which evidence applies and how researchers interpret changes in growth hormone signalling.
Once the terminology is clear, the comparison becomes much easier to understand.
CJC 1295 is a synthetic analogue of growth hormone releasing hormone (GHRH).
An analogue is a molecule designed to resemble a naturally occurring substance while containing selected structural changes.
GHRH is produced in the hypothalamus (a region of the brain involved in hormone regulation). It sends signals to the pituitary gland (a small gland below the brain), which releases growth hormone.
Growth hormone is not released at one constant level. It appears in pulses throughout the day and also contributes to the production of insulin like growth factor I (IGF I), a signalling protein made mainly by the liver.
CJC-1295 attracts research interest because it works through this existing GHRH pathway. It is not a growth hormone itself. Researchers have studied how it interacts with the signalling system that regulates growth hormone and IGF I.
The important detail is that adding or removing DAC changes how long the compound remains available within that pathway.
DAC stands for Drug Affinity Complex.
In the original CJC-1295 research, this modification was added so that the molecule could bind to albumin (the most abundant protein in blood plasma).
Albumin circulates for much longer than a small free peptide. When the DAC form attaches to albumin, the combined structure is cleared more slowly.
A useful way to picture this is to think of albumin as a slow moving carrier. The peptide remains connected to that carrier instead of being removed as quickly on its own.
In this 2005 study, scientists examined albumin binding versions of human GHRH in rats and cultured pituitary cells. CJC-1295 remained detectable in rat plasma beyond 72 hours, and laboratory testing produced evidence consistent with albumin binding.
This molecular design is why CJC 1295 with DAC is described as the long acting form.
As mentioned above, CJC-1295 with DAC contains the albumin binding modification. Published human research has therefore followed it across several days.
CJC-1295 without DAC is a related GHRH analogue that does not contain the same binding group. It is commonly described as modified GRF 1 to 29.
Without the connection to albumin, the compound is expected to follow a shorter time course. This gives it a different pharmacokinetic profile. Pharmacokinetics describes how a compound is distributed and cleared over time.
The two forms are connected through the same broad area of GHRH research, but their duration and evidence should be considered separately.
A 2024 FDA review described CJC 1295 without DAC and CJC 1295 with DAC as distinct active moieties. An active moiety is the part of a substance responsible for its biological activity. The review also noted that the forms are not interchangeable.
This is useful context when researching through reading material because the name CJC-1295 is not always used consistently.
The clearest human data relate to the DAC form.
In this 2006 study, healthy adults took part in randomised, placebo controlled and double blind trials.
This means that participants were assigned to groups by chance, an inactive comparison was included and the group assignments were concealed during the study.
The estimated half life of CJC 1295 with DAC was 5.8 to 8.1 days. Half life is the time required for the measured amount of a compound in the body to decrease by half.
Average growth hormone concentrations remained above baseline for at least six days after one administration, while average IGF I concentrations remained above baseline for nine to eleven days.
Baseline is the measurement recorded before an experimental condition begins.
These findings explain what long acting means in this context. The compound and its downstream signals were studied across days, not only during the first few hours.
Repeated administration also produced a cumulative pattern. Some of the earlier exposure was still present when later measurements were taken, which is expected when a compound has a multiday half life.
Growth hormone is naturally pulsatile, meaning that it is released through repeated peaks instead of remaining at a steady concentration.
Another 2006 study explored this pattern one week after a single administration of CJC 1295 with DAC in healthy men. Blood samples were collected every 20 minutes during a 12 hour overnight period.
The researchers found that the pulse frequency and pulse size were preserved. Average and trough growth hormone concentrations changed, but the pulsatile pattern remained.
A trough is the lower concentration measured between hormone peaks.
This finding adds helpful detail to the earlier study. CJC-1295 with DAC was associated with prolonged signalling, while growth hormone continued to appear in pulses.
It also explains why researchers may measure more than one marker. Growth hormone can change over minutes, while IGF I and the DAC form can be followed over a longer period.
CJC 1295 without DAC lacks the albumin binding feature, so it should not be assigned the 5.8 to 8.1 day half life measured for the DAC form.
Exact figures for the form without DAC are frequently repeated online. However, there is not the same matched human pharmacokinetic evidence establishing one widely accepted value.
That does not make the form without DAC more or less valuable as a research compound. It means that information needs to be matched to the exact molecule being discussed.
Older studies of GHRH analogues provide background on why this distinction matters. In this 1994 study, researchers compared two GHRH fragments in healthy men. A modified fragment had a disappearance half time of 6.7 minutes, compared with 4.3 minutes for the reference fragment.
The experiment did not test the commercial compound now described as CJC 1295 without DAC.
Its values should not be used as the confirmed half life of that product. It does show how small structural changes can alter the clearance of an unbound GHRH fragment.
The DAC distinction gives researchers two different ways to examine the GHRH pathway over time.
A long acting form creates a prolonged exposure window. This allows studies to follow growth hormone and IGF I signalling across several days and examine what happens when repeated exposures overlap.
A shorter acting form places more attention on the earlier part of the response. Researchers may need closer sampling near the beginning of the experiment to understand a narrower time course.
Neither profile is automatically better. They answer different research questions.
The choice of measurement matters as well. Measuring the compound shows how long it remains detectable. Measuring growth hormone examines pituitary signalling, while IGF I reflects a downstream signal that changes more slowly.
Understanding these differences makes research papers easier to compare and reduces the chance of applying findings from one form to the other.
Half life describes duration, not strength.
A compound that remains in circulation for longer may create more total exposure across time. Researchers sometimes describe this using area under the curve (a calculation of total measured exposure during a defined period).
The highest concentration, the total exposure and the duration are separate measurements. A longer half life does not show that one form is inherently better or that it produces a more meaningful biological response.
The useful comparison is between their time courses and the research questions each form can help explore.
The first question is whether the source means CJC-1295 with DAC or without DAC. If the literature quotes a half life measured in days, the original evidence should identify an albumin binding form.
The next question is what the researchers measured. A change in growth hormone, IGF I or peptide concentration describes a different part of the pathway.
Formulation is also important. A CJC-1295 without DAC and Ipamorelin blend contains two compounds that interact with separate receptors. Research on a combination cannot show the independent contribution of CJC 1295 unless suitable comparison groups are included.
Checking these details makes it easier to separate published evidence from general online descriptions.
Understanding the difference between CJC-1295 formulations can be overwhelming.
Our specialists offer 1:1 consultations to help you explore the research, compare terminology and understand where the evidence belongs.
You can schedule a consultation here.
CJC-1295 with DAC contains an albumin binding modification that extends its time in circulation. The form without DAC lacks this feature and follows a different pharmacokinetic profile.
DAC stands for Drug Affinity Complex. It allows the published CJC 1295 molecule to bind to albumin, which slows its clearance.
A 2006 human study estimated a half life of 5.8 to 8.1 days for CJC 1295 with DAC. This value should not be applied to the form without DAC.
Frequently quoted values are not supported by the same kind of matched human evidence available for the DAC form. Any figure should be checked against the precise compound studied.
Not necessarily. DAC changes duration and total exposure. Half life does not determine whether one form produces a stronger or more relevant biological response.
CJC 1295 is an analogue of GHRH, the hormone that signals the pituitary gland to release growth hormone. Research has therefore examined growth hormone and downstream IGF I signalling.
Written by Elizabeth Tito, BSc Genetics, MPH
Elizabeth is a science and medical writer specialising in peptide science, longevity medicine, mitochondrial health, metabolic optimisation and regenerative health research. With a BSc in Genetics and a Master’s in Public Health, she combines a strong scientific foundation with experience translating complex biomedical research into clear, clinically informed education for the Peptide Therapy and longevity medicine space. Her work is centred on interpreting emerging peptide, metabolic and longevity research with scientific accuracy, clinical awareness and a clear understanding of how these therapies are being discussed and applied in modern health optimisation.
